Highly polymorphic human CYP4A11 gene

Journal of Human Genetics

Volumn 50, Issue 5, 2005, Pages 259-263

  Cho, Byeong Hoon ^a   Park, Byung Lae ^a   Kim, Lyoung Hyo ^a   Chung, Hyun Sub ^a   Shin, Hyoung Doo ^a  

^a SNP Genetics Inc   (South Korea)

Author keywords

CYP450; CYP4A11; Single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450 4A11; DNA;

3' UNTRANSLATED REGION; ARTICLE; COMPARATIVE GENE MAPPING; DNA SEQUENCE; EXON; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INTRON; KOREA; NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POPULATION GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

3' UNTRANSLATED REGIONS; CYTOCHROME P-450 ENZYME SYSTEM; DNA; EXONS; GENE FREQUENCY; GENOTYPE; HUMANS; INTRONS; KOREA; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 21544469981     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-005-0245-9     Document Type: Article

References (17)

1. Adas F, Salaun JP, Berthou F, Picart D, Simon B, Amet Y (1999) Requirement for omega and (omega;-1)-hydroxylations of fatty acids by human cytochromes P450 2E1 and 4A11. J Lipid Res 40:1990-1997
2. Anttila S, Tuominen P, Hirvonen A, Nurminen M, Karjalainen A, Hankinson O, Elovaara E (2001) CYP1A1 levels in lung tissue of tobacco smokers and polymorphisms of CYP1A1 and aromatic hydrocarbon receptor. Pharmacogenetics 11:501-509
3. Baker JR, Satarug S, Edwards RJ, Moore MR, Williams DJ, Reilly PE (2003) Potential for early involvement of CYP isoforms in aspects of human cadmium toxicity. Toxicol Lett 137:85-93
4. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263-265
5. Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, Cupples LA, Guo CY, Demissie S, O'Donnell CJ, Brown NJ, Waterman MR, Capdevila JH (2005) Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 111:63-69
6. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF (2000) Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 60:3440-3444
7. Hedrick PW (1987) Gametic disequilibrium measures: proceed with caution. Genetics 117:331-341
8. Huang CY, Huang KL, Cheng TJ, Wang JD, Hsieh LL (1997) The GST T1 and CYP2E1 genotypes are possible factors causing vinyl chloride induced abnormal liver function. Arch Toxicol 71:482-488
9. Imaoka S, Ogawa H, Kimura S, Gonzalez FJ (1993) Complete cDNA sequence and cDNA-directed expression of CYP4A11, a fatty acid omega-hydroxylase expressed in human kidney. DNA Cell Biol 12:893-899
10. Johnson EF, Hsu MH, Savas U, Griffin KJ (2002) Regulation of P450 4A expression by peroxisome proliferator activated receptors. Toxicology 181-182:203-206
11. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett 263:131-133
12. Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK (2000) Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 275:4118-4126
13. McKinnon RA, Nebert DW (1994) Possible role of cytochromes P450 in lupus erythematosus and related disorders. Lupus 3:473-478
14. Okita RT, Okita JR (2001) Cytochrome P450 4A fatty acid omega hydroxylases. Curr Drug Metab 2:265-281
15. Powell PK, Wolf I, Lasker JM (1996) Identification of CYP4A11 as the major lauric acid omega-hydroxylase in human liver microsomes. Arch Biochem Biophys 335:219-226
16. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423
17. Yu S, Rao S, Reddy JK (2003) Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med 3:561-572